tbuckley/cabot-search huggingface dataset:
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Authors: Wei Chen, Maaike Schilperoort, Yihai Cao, Jinjun Shi, Ira Tabas, Wei Tao
Journal: Nature Reviews Cardiology (2021)

Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis and contribute to the development of novel diagnostic and therapeutic strategies to further reduce the risk of cardiovascular disease. Macrophages have key roles in atherosclerosis progression and, therefore, macrophage-associated pathological processes are important targets for both diagnostic imaging and novel therapies for atherosclerosis. In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in atherosclerotic plaques with the use of rationally designed nanoparticles. We review the latest progress in nanoparticle-based imaging modalities that can specifically target macrophages. Using novel molecular imaging technology, these modalities enable the identification of advanced atherosclerotic plaques and the assessment of the therapeutic efficacy of medical interventions. Additionally, we provide novel perspectives on how macrophage-targeting nanoparticles can deliver a broad range of therapeutic payloads to atherosclerotic lesions. These nanoparticles can suppress pro-atherogenic macrophage processes, leading to improved resolution of inflammation and stabilization of plaques. Finally, we propose future opportunities for novel diagnostic and therapeutic strategies and provide solutions to challenges in this area for the purpose of accelerating the clinical translation of nanomedicine for the treatment of atherosclerotic vascular disease.
Transcriptomes of Major Proximal Tubule Cell Culture Models
Authors: K. S. Dorans, J. A. Wright Nunes, D. E. Schaubel, D. Sha, M. Rahman, H. I. Feldman
Journal: Journal of the American Society of Nephrology (2020)

Background Cultured cell lines are widely used for research in the physiology, pathophysiology, toxicology, and pharmacology of the renal proximal tubule. The lines that are most appropriate for a given use depend upon the genes expressed. New tools for transcriptomic profiling using RNA sequencing (RNA-Seq) make it possible to catalog expressed genes in each cell line. Methods Fourteen different proximal tubule cell lines, representing six species, were grown on permeable supports under conditions specific for the respective lines. RNA-Seq followed standard procedures. Results Transcripts expressed in cell lines variably matched transcripts selectively expressed in native proximal tubule. Opossum kidney (OK) cells displayed the highest percentage match (45% of proximal marker genes [TPM threshold =15]), with pig kidney cells (LLC-PK1) close behind (39%). Lower-percentage matches were seen for various human lines, including HK-2 (26%), and lines from rodent kidneys, such as NRK-52E (23%). Nominally, identical OK cells from different sources differed substantially in expression of proximal tubule markers. Mapping cell line transcriptomes to gene sets for various proximal tubule functions (sodium and water transport, protein transport, metabolic functions, endocrine functions) showed that different lines may be optimal for experimentally modeling each function. An online resource ( https://esbl.nhlbi.nih.gov/JBrowse/KCT/ ) has been created to interrogate cell line transcriptome data. Proteomic analysis of NRK-52E cells confirmed low expression of many proximal tubule marker proteins. Conclusions No cell line fully matched the transcriptome of native proximal tubule cells. However, some of the lines tested are suitable for the study of particular metabolic and transport processes seen in the proximal tubule.
Patient Reported Outcomes in Patients with Newly Diagnosed <i>FLT3</i>mut+ acute Myeloid Leukemia Ineligible for Intensive Induction Chemotherapy from Lacewing: A Randomized Phase 3 Trial of Gilteritinib and Azacitidine Versus Azacitidine Alone
Authors: Eunice S. Wang, Michael Heuser, Pau Montesinos, Elizabeth Shima Rich, Ruishan Wu, Bhavik J. Pandya, Manasee V. Shah
Journal: Blood (2021)
Harnessing Tissue-derived Extracellular Vesicles for Osteoarthritis Theranostics
Authors: Bohan Yin, Junguo Ni, Claire E. Witherel, Mo Yang, Jason A. Burdick, Chunyi Wen, Siu Hong Dexter Wong
Journal: Theranostics (2021)

Osteoarthritis (OA) is a prevalent chronic whole-joint disease characterized by low-grade systemic inflammation, degeneration of joint-related tissues such as articular cartilage, and alteration of bone structures that can eventually lead to disability. Emerging evidence has indicated that synovium or articular cartilage-secreted extracellular vesicles (EVs) contribute to OA pathogenesis and physiology, including transporting and enhancing the production of inflammatory mediators and cartilage degrading proteinases. Bioactive components of EVs are known to play a role in OA include microRNA, long non-coding RNA, and proteins. Thus, OA tissues-derived EVs can be used in combination with advanced nanomaterial-based biosensors for the diagnostic assessment of OA progression. Alternatively, mesenchymal stem cell- or platelet-rich plasma-derived EVs (MSC-EVs or PRP-EVs) have high therapeutic value for treating OA, such as suppressing the inflammatory immune microenvironment, which is often enriched by pro-inflammatory immune cells and cytokines that reduce chondrocytes apoptosis. Moreover, those EVs can be modified or incorporated into biomaterials for enhanced targeting and prolonged retention to treat OA effectively. In this review, we explore recently reported OA-related pathological biomarkers from OA joint tissue-derived EVs and discuss the possibility of current biosensors for detecting EVs and EV-related OA biomarkers. We summarize the applications of MSC-EVs and PRP-EVs and discuss their limitations for cartilage regeneration and alleviating OA symptoms. Additionally, we identify advanced therapeutic strategies, including engineered EVs and applying biomaterials to increase the efficacy of EV-based OA therapies. Finally, we provide our perspective on the future of EV-related diagnosis and therapeutic potential for OA treatment.
Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients
Authors: Kalpana Parvathaneni, Kyabeth Toress-Rodriguez, Wenzhao Meng, James Knox, Xiaoming Xu, Daniela Weiskopf, Noelle V Frey, Eline Luning-Prak, Alfred L Garfall, Michael Betts, Wei-Ting Hwang, David L Porter, Carl H June, Ali Naji, Vijay Bhoj
Journal: Blood (2021)
Enasidenib in Combination with Venetoclax in <i>IDH2</i>-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial
Authors: Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara
Journal: Blood (2021)
OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
Authors: Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei
Journal: Blood (2021)
Mesenchymal Stromal Cells (MSCs) from Myelodysplastic Syndromes (MDS) Are Not Clonally Mutated I <i>n Vivo</i>
Authors: Johann-Christoph Jann, Maximilian Mossner, Vladimir Riabov, Eva Altrock, Nanni Schmitt, Johanna Flach, Qingyu Xu, Verena Nowak, Julia Obländer, Iris Palme, Nadine Weimer, Alexander Streuer, Ahmed Jawhar, Ali Darwich, Georgia Metzgeroth, Florian Nolte, Wolf-Karsten Hofmann, Daniel Nowak
Journal: Blood (2021)
Covid-19: Hospitals move to create extra bed capacity to relieve pressure
Authors: Gareth Iacobucci
Journal: BMJ (2021)

NHS hospitals across the UK are creating extra bed capacity to relieve ongoing operational pressures from covid-19 and to tackle the growing backlog in elective care. Reports are increasing of trusts being forced to cancel elective operations in the face of major pressure on services (box 1), and ongoing bed shortages are prompting some trusts to add more capacity. Box 1 ### Elective operations cancelled Last week it was reported that most elective surgery had been cancelled at the Princess Alexandra Eye Pavilion in Edinburgh until March 2022 to allow staff to be redeployed to the nearby Edinburgh Royal Infirmary.1 Meanwhile, five hospitals in Leeds were reported to have cancelled most "priority 2" elective operations on Tuesday 2 November after a surge in numbers of patients with covid-19 and in the emergency department.2 In a statement Mark Liddington, medical director of operations for planned care at Leeds Teaching Hospitals NHS Trust, confirmed that said some procedures "that are not assessed as clinically urgent" had been postponed but said "the situation has … RETURN TO TEXT
Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
Authors: Akriti G Jain, Ning C. Dong, Somedeb Ball, Elaine S Tan, Junmin Whiting, Rami S. Komrokji, Kendra Sweet, Onyee Chan, David A. Sallman, Eric Padron, Andrew T. Kuykendall, Anna Giuliano, Jeffrey E. Lancet
Journal: Blood (2021)
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant <i>BCR-ABL1 T315I</i>-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
Authors: Jiang Qian, Dayu Shi, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yongping Song, Gongli Zhang, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yujun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood (2021)
Successful Quality Improvement Projects to Maximize Prescription Rates and Acceptance of Hydroxyurea Among Patients with Sickle Cell Anemia
Authors: Ofelia A. Alvarez, Sandra Echenique, E. Leila Jerome Clay, Hector Rodriguez-Cortes, Thomas J. Harrington, Mildred E Berry, Mary Murph, Christopher Wells, Cheryl Courtlandt, Laura Noonan
Journal: Blood (2021)
Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma
Authors: Matthew J. Frigault, Jorg Dietrich, Kathleen M.E. Gallagher, Irene Scarfò, Mark Roschewski, Justin T Jordan, Deborah A. Forst, Scott R Plotkin, Daniella Cook, Keagan Casey, Katelin Katsis, Kevin Lindell, Michael Trailor, Nora Horick, Steven McAfee, Paul V O'Donnell, Thomas R Spitzer, Bimalangshu R Dey, Zachariah Defilipp, Areej El-Jawahri, Tracy Batchelor, Marcela V. Maus, Yi-Bin Chen
Journal: Blood (2021)
Measles outbreaks likely as covid pandemic leaves millions of world’s children unvaccinated, WHO warns
Authors: Ingrid Torjesen
Journal: BMJ (2021)

s children unvaccinated, WHO warns Ingrid TorjesenThe risk of outbreaks of measles across the world is mounting because the covid-19 pandemic caused millions of children to miss out on essential vaccinations and has severely affected disease surveillance systems, says a report from the World Health Organization and the US Centers for Disease Control and Prevention.
Survivorship Issues in Adult Patients With Histiocytic Neoplasms
Authors: Kevin O’Brien, Rahul Dave, Skand Shekhar, Fady Hannah-Shmouni, Leora E. Comis, Beth I. Solomon, Marcus Chen, William A. Gahl, Edmond FitzGibbon, Bernadette R. Gochuico, Juvianee I. Estrada-Veras
Journal: Journal of the National Comprehensive Cancer Network (2021)

Adult-onset histiocytoses (AOH), primarily Rosai-Dorfman disease (RDD), Erdheim-Chester Disease (ECD), and adult Langerhans cell histiocytosis (ALCH), are a group of related histiocytic neoplastic disorders featuring multisystemic manifestations. The disorders are largely incurable, and are essentially chronic neoplastic diseases with a variable prognosis. Prompt diagnosis and treatment is important to prevent debilitating and even life-threatening complications. Survivorship issues abound in AOH, due to their multisystemic manifestations and the sometimes recalcitrant chronic inflammation, which can lead to other debilitating complications such as fatigue, weakness, and pain. Because these disorders are rare, few healthcare professionals are proficient in their management; therefore the aim of these guidelines is to offer guidance on how to manage patients, and how to create survivorship care plans through the efforts of an interdisciplinary team.
Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
Authors: Annalisa Ruggeri, Antonio Voza, Carmine Liberatore, Gloria Catalano, Francesco Corrado, Luigi Di Filippo, Rosamaria Nitti, Carlo Fedeli, Alessandro Bruno, Eleonora Calabretta, Fabio Giglio, Fabio Sciutti, Francesca Lunghi, Giovanni Landoni, Paul G. Richardson, Massimo Iacobelli, Alessio Aghemo, Patrizia Rovere-Querini, Andrea A. Assanelli, Jacopo Peccatori, Fabio Ciceri, Carmelo Carlo-Stella
Journal: Blood (2021)
Anti-PD-1-Antibody (Tislelizumab) Combined with Deacetylase Inhibitor (Chidamide), Lenalidomide and Etoposide for the Treatment of Refractory/Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial
Authors: Lei Zhang, Xiyang Liu, Xinhua Wang, Yu Chang, Xiaorui Fu, Xin Li, Ling Li, Jiaqin Yan, Feifei Nan, Xiaolong Wu, Linan Zhu, Zhenchang Sun, Hui Yu, Mingzhi Zhang
Journal: Blood (2021)
Last-Minute Pedicure
Authors: Judith Harris
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association between Megakaryocyte Abnormalities on Bone Marrow Smear and Response to Thrombopoietin Receptor Agonists in Adult Patients with Primary Immune Thrombocytopenia
Authors: Ondine Walter, Agnès Ribes, Johanne Germain, Jean-Baptiste Rieu, Thibault Comont, Albertine Plat, Brigitte Rivière, Lauréline Deluche, Lucrecia Delarue, Isabelle Le Goff, Monique Greze, Béatrice Dubourdieu, Odile Beyne-Rauzy, Veronique De Mas, Guillaume Moulis
Journal: Blood (2021)
A Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Celltransplantation for Patients with Primary or Secondary Myelofibrosis
Authors: Gabriela Hobbs, Haesook T. Kim, AJ S. Bottoms, Michael T. Byrne, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Zachariah Defilipp, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen
Journal: Blood (2021)
A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (<i>FGFR)</i> 1 Rearrangements
Authors: Jean-Jacques Kiladjian, Kohei Shitara, Lee Stephen Rosen, Sun Young Rha, Aiwu He, Do-Youn Oh, Davide Melisi, Satoru Iwasa, Yixing Jiang, Sherry Liu, Osamu Takahashi, Vincent Ribrag
Journal: Blood (2021)
KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries
Authors: Joshua A Fein, Roni Shouval, Elizabeth Krieger, Henning Baldauf, Katharina Fleischhauer, Nicolaus Kroeger, Mary M. Horowitz, Martin Maiers, Karl-Johan Malmberg, Jeffrey S. Miller, Mohamad Mohty, Arnon Nagler, Rizwan Romee, Johannes Schetelig, Stephen R. Spellman, Amir Ahmed Toor, Tao Wang, Daniel J. Weisdorf, John Koreth
Journal: Blood (2021)
Automated Quantification of Chronic Changes in the Kidney Biopsy: Another Step in the Right Direction
Authors: Jeffrey B. Hodgin, Laura H. Mariani
Journal: Journal of the American Society of Nephrology (2021)

Increased availability of whole-slide scanning technology and advancements in computational image analysis hold promise to improve the utility of the kidney biopsy by allowing automated pipelines to identify and quantify structural alterations in the tissue.[1][1] Current disease classifications on
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Authors: Christian Récher, Christoph Röllig, Emilie Bérard, Sarah Bertoli, Pierre-Yves Dumas, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Arnaud Pigneux, Pau Montesinos
Journal: Leukemia (2021)

Abstract The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients ≥70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy ( n = 1199) or hypomethylating agents ( n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7–11.6) and 9.2 months (95% CI: 8.3–10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively ( P &lt; 0.0001). Treatment effect on overall survival was time-dependent. The Royston and Parmar model showed that patients treated with hypomethylating agents had a significantly lower risk of death before 1.5 months of follow-up; no significant difference between 1.5 and 4.0 months, whereas patients treated with intensive chemotherapy had a significantly better overall survival from four months after start of therapy. This study shows that intensive chemotherapy remains a valuable option associated with a better long-term survival in older AML patients.
ASPP2 <i>k</i>, a Dominant-Negative Splicing Variant of the Apoptosis-Stimulating Protein of p53-2 (ASPP2), Modulates Treatment Response Towards BCL-Signaling Inhibitors in Acute Myeloid Leukemia
Authors: Marcus M. Schittenhelm, Vasileia Tsintari, Rebecca Fröhlich, Kerstin Maria Kampa-Schittenhelm
Journal: Blood (2021)
Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology
Authors: Lisa K. Hicks, Robert A. Redd, Kenneth C. Anderson, Pinkal Desai, Brendan Dolan, Aaron D Goldberg, Varun Narendra, Donna S. Neuberg, Vivek Radhakrishnan, Laurie H. Sehn, Mikkael A. Sekeres, Maximilian Stahl, Martin S. Tallman, John Colton Thompson, Emily Tucker, William A. Wood
Journal: Blood (2021)
Validation of Pre-Transplantation Plasma ST2 Levels As a Prognostic Marker of 1-Year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation
Authors: Lars Klingen Gjaerde, Sisse Rye Ostrowski, Frederikke Schierbeck, Niels Smedegaard Andersen, Lone Smidstrup Friis, Brian Thomas Kornblit, Søren Lykke Petersen, Ida Schjødt, Henrik Sengeloev
Journal: Blood (2021)
Robust deep learning-based semantic organ segmentation in hyperspectral images
Authors: Silvia Seidlitz, Jan Sellner, Jan Odenthal, Berkin Özdemir, Alexander Studier-Fischer, Samuel Knödler, Leonardo Ayala, Tim J. Adler, Hannes G. Kenngott, Minu Tizabi, Martin Wagner, Felix Nickel, Beat P. Müller-Stich, Lena Maier-Hein
Journal: Medical Image Analysis (2022)

Semantic image segmentation is an important prerequisite for context-awareness and autonomous robotics in surgery. The state of the art has focused on conventional RGB video data acquired during minimally invasive surgery, but full-scene semantic segmentation based on spectral imaging data and obtained during open surgery has received almost no attention to date. To address this gap in the literature, we are investigating the following research questions based on hyperspectral imaging (HSI) data of pigs acquired in an open surgery setting: (1) What is an adequate representation of HSI data for neural network-based fully automated organ segmentation, especially with respect to the spatial granularity of the data (pixels vs. superpixels vs. patches vs. full images)? (2) Is there a benefit of using HSI data compared to other modalities, namely RGB data and processed HSI data (e.g. tissue parameters like oxygenation), when performing semantic organ segmentation? According to a comprehensive validation study based on 506 HSI images from 20 pigs, annotated with a total of 19 classes, deep learning-based segmentation performance increases, consistently across modalities, with the spatial context of the input data. Unprocessed HSI data offers an advantage over RGB data or processed data from the camera provider, with the advantage increasing with decreasing size of the input to the neural network. Maximum performance (HSI applied to whole images) yielded a mean DSC of 0.90 ((standard deviation (SD)) 0.04), which is in the range of the inter-rater variability (DSC of 0.89 ((standard deviation (SD)) 0.07)). We conclude that HSI could become a powerful image modality for fully-automatic surgical scene understanding with many advantages over traditional imaging, including the ability to recover additional functional tissue information. Code and pre-trained models: https://github.com/IMSY-DKFZ/htc.
Epigenome-Wide Association Study of Acute Lymphoblastic Leukemia in Children with Down Syndrome
Authors: Shaobo Li, Pagna Sok, Keren Xu, Ivo S Muskens, Natalina Elliott, Swe Swe Myint, Priyatama Pandey, Helen M Hansen, Libby M Morimoto, Alice Y Kang, Catherine Metayer, Xiaomei Ma, Beth A Mueller, Anindita Roy, Irene Roberts, Karen R Rabin, Austin L Brown, Philip J. Lupo, Joseph L. Wiemels, Adam J. de Smith
Journal: Blood (2021)
Cepp in Previously Untreated Patients with Mature T Cell Lymphomas
Authors: Hian Li Esther Chan, Joanne Lee, Sanjay De Mel, Anand Devaprasath D. Jeyasekharan, Yen Lin Chee, Lay Poh Khoo, Yong Sheng Jason Chan, Soon Thye Lim, Michelle Poon, Nagavalli Somasundaram
Journal: Blood (2021)
Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study
Authors: William Pilcher, Beena E Thomas, Swati S Bhasin, Reyka G Jayasinghe, Adeeb H Rahman, Seunghee Kim-Schulze, Edgar Gonzalez-Kozlova, Taxiarchis Kourelis, Madhav V Dhodapkar, Ravi Vij, Shaji Kumar, Shaadi Mehr, Mark Hamilton, Hearn Jay Cho, Daniel Auclair, David Avigan, Sacha Gnjatic, Li Ding, Manoj Bhasin
Journal: Blood (2021)
Gda-201, a Novel Metabolically Enhanced Allogeneic Natural Killer (NK) Cell Product Yields High Remission Rates in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL): 2-Year Survival and Correlation with Cytokine IL7
Authors: Veronika Bachanova, Joseph E. Maakaron, Frank Cichocki, David H. McKenna, Qing Cao, Todd E. DeFor, Murali Janakiram, Rose Wangen, Zuzan Cayci, Bartosz Grzywacz, Ronit Simantov, Tracey Lodie, Jeffrey S. Miller
Journal: Blood (2021)